Merck and Ridgeback Biotherapeutics Announce Initiation of Pivotal Phase 3 MOVe-AHEAD Study Evaluating Molnupiravir for Post-Exposure Prophylaxis of COVID-19 InfectionBusiness Wire • 09/01/21
FDA Approves Updated Indication for Merck's KEYTRUDA® (pembrolizumab) for Treatment of Certain Patients With Urothelial Carcinoma (Bladder Cancer)Business Wire • 08/31/21
3 of the Dow's Worst-Performing Stocks Over the Trailing Year Are Now Screaming BuysThe Motley Fool • 08/31/21
Merck Announces VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) Met Key Immunogenicity and Safety Endpoints in Phase 3 Pivotal Trial Evaluating Use in Infants, PNEU-PED (V114-029)Business Wire • 08/25/21
Warren Buffett's Berkshire Hathaway sold Biogen, halved its Merck stake, and boosted its Kroger bet. Here's a closer look at its key trades in Q2.Business Insider • 08/17/21